The DePuy ASR hip implant claims are being directed through Broadspire, a leading third-party administrator to employers and insurance companies. Few of those harmed by the implant are fully cognizant of the extreme level of sophistication of such firms.

Even after the FDA raised concerns regarding the safety of the DePuy ASR hip implants in 2009, Johnson & Johnson forged ahead with the sale of implants in their inventory prior to finally discontinuing the devices. The DePuy ASR XL hip replacement system was approved through the 510(k) FDA process in 2005—a process requiring no human testing.

Even after the FDA raised concerns regarding the safety of the DePuy ASR hip implants in 2009, Johnson & Johnson forged ahead with the sale of implants in their inventory prior to finally discontinuing the devices. The DePuy ASR XL hip replacement system was approved through the 510(k) FDA process in 2005—a process requiring no human testing.

The U.S. Drug Watchdog has a goal of identifying every single one of the more than 130,000 Americans who received the DePuy Pinnacle hip implant constructed of a metal ball and joint, between the years of 2005 and 2010. In an effort to ensure no recipient of the implant who suffered harm is left behind, the initiative to reach all of those exposed to the potential dangers is considered extremely important.

DePuy Orthopedics sent out a letter known as the “Broadspire Letter” to those people who had received a DePuy ASR metal-on-metal hip implant. The overall message of this letter was to let patients know that the ASR had been recalled due to a “small number” of patients who had experienced problems with their hip implant.